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ABSTRACT
Quinolones inhibit bacterial type II DNA topoisomer-
ases (e.g. DNA gyrase) and are among the most
important antibiotics in current use. However, their
efficacy is now being threatened by various plasmid-
mediated resistance determinants. Of these, the
pentapeptide repeat-containing (PRP) Qnr proteins
are believed to act as DNA mimics and are particu-
larly prevalent in Gram-negative bacteria. Predicted
Qnr-like proteins are also present in numerous
environmental bacteria. Here, we demonstrate that
one such, Aeromonas hydrophila AhQnr, is sol-
uble, stable, and relieves quinolone inhibition
of Escherichia coli DNA gyrase, thus providing an
appropriate model system for Gram-negative Qnr
proteins. The AhQnr crystal structure, the first for
any Gram-negative Qnr, reveals two prominent
loops (1 and 2) that project from the PRP structure.
Deletion mutagenesis demonstrates that both con-
tribute to protection of E. coli DNA gyrase from quin-
olones. Sequence comparisons indicate that these
are likely to be present across the full range of
Gram-negative Qnr proteins. On this basis we
present a model for the AhQnr:DNA gyrase inter-
action where loop1 interacts with the gyrase A
‘tower’ and loop2 with the gyrase B TOPRIM
domains. We propose this to be a general mechan-
ism directing the interactions of Qnr proteins with
DNA gyrase in Gram-negative bacteria.
INTRODUCTION
Quinolones, particularly ﬂuoroquinolones, are among the
most widely used antibiotics on account of their broad
spectrum of activity that encompasses many pathogenic
Gram-negative (Enterobacteriaceae) and Gram-positive
(staphylococci and streptococci) bacteria (1,2). They are
particularly effective against urinary tract and sexually
acquired infections, but more recently have found appli-
cation in the treatment of gastrointestinal, skin and soft
tissue, bone and joint and some respiratory infections.
Newer ﬂuoroquinolones (oﬂoxacin, gatiﬂoxacin,
moxiﬂoxacin) also show promise as candidates for inclu-
sion in multidrug anti-tuberculosis therapy (3).
Quinolones target the bacterial type IIA DNA topoisom-
erases DNA gyrase and DNA topoisomerase IV. These
heterotetrameric enzymes manipulate DNA topology by
introduction of transient double-stranded breaks in bound
DNA (G-segment) through which a second DNA
fragment (T-segment) may be passed (4). Binding, by
intercalation (5), of quinolone antibiotics to the complex
of enzyme and the cut G-segment stabilizes this so-called
cleavage complex, leading to accumulation, and even-
tual release, of double-stranded DNA breaks that are
ultimately lethal to the cell (6).
As quinolones are fully-synthetic drugs, transferable re-
sistancewaslongconsideredtobeunlikelyintheabsenceof
a pool of environmental resistance genes emanating from
producer organisms. Until recently, quinolone resistance
was known to arise by mutation of speciﬁc regions of
type IIA DNA topoisomerases [the quinolone resistance
determinant region (QRDR) (7)] and/or by the acquisition
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situation has changed markedly with the discovery of a
variety of plasmid-borne resistance determinants
[reviewed in ref. (9)]. These include the DNA topoisomer-
ase protection protein Qnr (10,11), the ﬂuoroquinolone
acetyltransferase Aac(60)-Ib-cr (12) and transferable
ﬂuoroquinolone efﬂux pumps such as QepA (13) and
OqxAB (14,15). Of these, the mechanism by which expres-
sion of qnr confers clinical ﬂuoroquinolone resistance is the
least understood.
Qnr was ﬁrst identiﬁed in the early 1990s as a
plasmid-borne gene in a clinical strain of Klebsiella
pneumoniae (11). Subsequent investigations have estab-
lished that qnr genes have a worldwide distribution in a
range of (mainly Gram-negative opportunist) bacterial
pathogens, particularly Enterobacteriaceae (e.g. Klebsiella
pneumoniae, Escherichia coli) (16). New family members
continue to be described (17,18). Sequence comparison of
plasmids isolated from clinical Gram-negative strains dif-
ferentiates ﬁve distinct qnr subfamilies: qnrA (A1–A7),
qnrB (B1–B25), qnrS (S1–S4) (19) and most recently qnrC
(17) and qnrD (18). While high levels of amino acid
sequence conservation ( 90% similarity) are observed
between members of the same subfamily, the ﬁve different
subfamilies are less closely related (60% similarity or less).
Furthermore, qnr-like open reading frames (orfs) are
present upon the chromosomes of numerous other
bacteria, including both Gram-positive organisms such as
enterococci (20) and mycobacteria (21) and a range of en-
vironmental Gram-negative organisms [e.g. Shewanella
(22), Stenotrophomonas (23,24) and Vibrio (25,26) spp.].
The relationship between these qnr-like orfs and the qnr
genes found in clinical isolates varies—qnrA is essentially
identical to orfs found in strains of Shewanella algae (22),
whereas chromosomal qnr-like genes from other organisms
may be more distantly related to qnrs of clinical origin
[Supplementary Figures S1 and S2; (23)].
The sequences of Qnr and related proteins are largely
composed of degenerate pentapeptide repeats. Crystal
structures, now available for Qnr-like proteins from
Mycobacterium tuberculosis [MfpA; (27)] and
Enterococcus faecalis [EfsQnr; (28,29)], as well as for a
number of other pentapeptide repeat proteins [PRPs;
(30–33)] show that these sequences fold to a distinctive
right-handed b-helix. In the case of MfpA and EfsQnr,
the dimensions and surface charge distribution of this
helix approximate to those of B-form DNA (27).
Accordingly, it has been suggested that Qnr and related
proteins act as DNA mimics that compete with DNA for
binding to type IIA DNA topoisomerases. Consistent with
this observation, MfpA binds directly to the DNA gyrase
holoenzyme (27), while QnrA binds to both the DNA
gyrase and DNA topoisomerase IV holoenzymes and to
their constituent subunits (34,35). However, different
pentapeptide repeat proteins affect DNA topoisomerase
activity in different ways. MfpA is a potent inhibitor of
DNA gyrase in the absence of antibiotics (27,36), whereas
forQnrproteins(QnrB4)thiseffectisonlyweaklyobserved
(36). QnrA1 (34,37), QnrB1 (38) and QnrB4 (36) all protect
DNA gyrase from inhibition by ﬂuoroquinolones, whereas
no such effect has been demonstrated for MfpA (36).
QnrA1 also shows equivalent protection of DNA topo-
isomerase IV (35). Very recently, EfsQnr was shown to
act both as a DNA gyrase inhibitor and to partially
protect the enzyme from inhibition by ciproﬂoxacin (29).
Many aspects of the mechanism of action of Qnr
proteins are thus unclear. It remains to be established:
(i) why inhibition of DNA gyrase activity varies between
different pentapeptide repeat proteins and (ii) how Qnr
proteins counteract quinolone inhibition of type IIA
DNA topoisomerases without overly affecting the
normal function of these essential cellular enzymes.
Furthermore, to date no Qnr or Qnr-related protein
from a Gram-negative organism has been structurally
characterized, an important consideration as the
majority of known Qnr proteins from both clinical and
environmental sources are of Gram-negative origin. Our
initial investigations, using K. pneumoniae QnrB2, were
hampered by the poor solubility of the recombinant
protein, while we also experienced difﬁculty in expressing
recombinant QnrS1. Accordingly, we here use a bioinfor-
matics approach to identify AhQnr, a Qnr-like protein
encoded on the chromosome of the Gram-negative
aquatic bacterium [and occasional opportunist pathogen,
(39)] Aeromonas hydrophila, as a Qnr family member of
predicted high solubility, and demonstrate that AhQnr is
readily over-expressed and puriﬁed from recombinant
E. coli. AhQnr protects DNA gyrase from quinolone in-
hibition in a similar fashion to previously characterized
Qnr proteins, and is thus a suitable model system in
which to undertake biophysical and structural studies of
Qnr proteins. The crystal structure of AhQnr reported
here is, however, distinguished from those of previously
reported family members from Gram-positive bacteria
(MfpA and EfsQnr) by possession of two distinctive
loops projecting from the overall b-helix structure.
Deletion of the larger of these abolishes the ability of
AhQnr to protect DNA gyrase from inhibition by the
ﬂuoroquinolone ciproﬂoxacin. Sequence comparisons
indicate that both of these loops are conserved in Qnr
proteins from other Gram-negative species of both envir-
onmental and pathogenic origin, with the larger one being
highly conserved. Our results suggest a speciﬁc mechanism
directing interactions of Qnr proteins from Gram-negative
bacteria with DNA gyrase.
MATERIALS AND METHODS
AhQnr cloning, expression and puriﬁcation
Detailed procedures are given in Supplementary Data.
The qnr-like open reading frame AhQnr (GenBank acces-
sion no. ABK38882.1, from the chromosome of
Aeromonas hydrophila ATCC 7966; generous gift of Dr
Antonio Corriea, University of Aveiro, Portugal) was
cloned into the T7 expression vector pET-26b
(Novagen) by standard procedures. Recombinant
protein was puriﬁed from E. coli strain BL21 (DE3) or
B834 (DE3) (selenomethionine-substituted material) by
anion exchange, heparin afﬁnity and size exclusion
chromatography.
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Circular dichroism (CD) spectra were measured on a
JASCO J-815 spectropolarimeter ﬁtted with a Peltier tem-
perature controller. AhQnr solutions were dialyzed into
buffer D (20mM sodium phosphate pH 8.0, 10%
glycerol) and prepared in 1mm path-length cuvettes.
Spectra were recorded at 5 C using a 1nm interval, 1nm
bandwidth and 2s response time.
Analytical ultracentrifugation
AhQnr in buffer D was diluted to concentrations of 10.6,
7.0 and 5.3mM. Samples were centrifuged at 10 000, 12 000
and 14000rpm at 10 C in 12mm path-length cells in a
Beckman XL-I analytical ultracentrifuge until sedimenta-
tion had reached equilibrium, and absorbance at 280nm
was recorded as a function of centrifugal radius. Data were
ﬁtted globally using UltraScan [http://www.ultrascan
.uthscsa.edu/; (40)] with the partial speciﬁc volume
(0.7205ml/g) and the solvent density (1.0311g/ml)
calculated, based on the sequence of AhQnr and buffer
composition, using SEDNTERP (41). Fits were evaluated
on the basis of random variation in the residuals, where
the residuals represent the difference between each data
point and the corresponding theoretical point on the
ﬁtted curve. For data plotting absorbance readings were
converted to protein concentration using an extinction
coefﬁcient of 22970M
 1 cm
 1 calculated from the
AhQnr amino acid sequence using the algorithm of Gill
and von Hippel (42).
DNA gyrase supercoiling assays
Assays were carried out using a commercial E. coli DNA
gyrase supercoiling assay kit (Inspiralis, Norwich, UK) in
a total reaction volume of 30ml. Relaxed plasmid pBR322
(500ng) was incubated with DNA gyrase in the supplied
buffer (35mM Tris–HCl pH 7.5, 24mM KCl, 2mM DTT,
1.8mM spermidine, 1mM ATP, 6.5% glycerol, 0.1mg/ml
BSA) with appropriate amounts of ciproﬂoxacin and
AhQnr in buffer D (AhQnr) or buffer H (25mM Tris-
HCl pH 7.5, 2mM DTT, 5% glycerol; AhQnr-6His and
mutants) for 1h at 37 C. The entire reaction was loaded
on a 1% agarose gel in 1 TAE buffer for electrophoresis
(2V/cm, 16h). Gels were stained in 1 TAE buffer sup-
plemented with 1mg/ml ethidium bromide and visualized
under UV illumination.
Crystallization and structure determination
Full methods for crystallization and structure determin-
ation are given in Supplementary Data. Brieﬂy, AhQnr
was crystallized by hanging-drop vapour diffusion from
0.1M sodium cacodylate pH 6.8, 1.5M sodium acetate,
20mM DTT, yielding crystals of orthorhombic symmetry
that diffracted to 2.2A ˚ resolution at beamline 10.1 of the
SRS, Daresbury, UK. As this single crystal could not be
reproduced we re-screened for additional crystal forms
using protein modiﬁed by reductive methylation of
surface lysine residues (43). Crystals diffracting to 2.0A ˚
resolution at beamline I03 of the Diamond Light Source
grew from 0.1M bis–tris propane pH 7.5, 0.2M potassium
thiocyanate, 16–20% PEG 3350, 8–16% glycerol, 40mM
DTT, 20mM spermine–HCl. These were reproduced for
selenomethionine (SeMet)-substituted protein and a 9-fold
redundant data set to 3.0A ˚ resolution collected at the Se
absorption edge (maximal f00) at Diamond beamline I02.
The structure was solved by a combination of single-
wavelength anomalous dispersion (SAD) and molecular
replacement as described in Supplementary Data, with
subsequent phase extension and reﬁnement against the
native data set. The reﬁned structure was then used as a
search model to solve the structure of the orthorhombic
crystal form by molecular replacement. Data collection
and reﬁnement statistics are given in Table 1.
Data deposition
Co-ordinates and structure factors for the structures of
AhQnr in the monoclinic and orthorhombic crystal
forms have been deposited with the Protein Data Bank
(www.rcsb.org/pdb) with accession codes 3PSS and
3PSZ for release upon publication. The co-ordinates of
the modeled complex of AhQnr and the E. coli GyrA
59kDa and GyrB TOPRIM fragments are available for
download from http://www.bristol.ac.uk/cellmolmed/
staff/spencer.html.
Table 1. Data collection and reﬁnement statistics
Native SeMet-SAD Orthorhombic
Data collection
X-ray source DIAMOND I03 DIAMOND I02 SRS 10.1
Wavelength (A ˚ ) 0.97630 0.97920 1.11700
Space group P21 P21 P21212
Cell dimensions
a, b, c (A ˚ ) 52.23, 57.71, 85.12 52.45, 57.67, 86.22 88.73, 116.2, 55.10
a, b, g ( ) 90, 106.96, 90 90, 107.25, 90 90, 90, 90
Resolution (A ˚ ) 49.96–2.00 49.86–3.00 43.43–2.20
(2.11–2.00) (3.16–3.00) (2.32–2.20)
Rmerge 0.101 (0.562) 0.052 (0.086) 0.132 (0.424)
No. reﬂections
(total)
237955 (34930) 178653 (26231) 127598 (17522)
No. reﬂections
(unique)
32765 (4744) 10020 (1442) 28777 (4050)
I/sI 12.8 (3.5) 47 (29.4) 8 (3.1)
Completeness (%) 99.9 (99.9) 99.8 (100) 98.1 (98.6)
Redundancy 7.3 (7.4) 9.1 (9.2) 4.4 (4.3)
Reﬁnement
Resolution (A ˚ ) 2.0 2.2
No. reﬂections 32 807 29 576
Rwork/Rfree 17.87/23.28 21.08/26.99
No. atoms
Protein 3422 3409
Ligand/ion 0 91
Water 302 249
B-factors
Protein 34.785 19.689
Ligand/ion 38.934
Water 37.651 26.411
R.m.s.d.
Bond lengths (A ˚ ) 0.0095 0.0118
Bond angles ( ) 1.2112 1.3641
Figures in parentheses relate to data collected in the highest resolution
shell. Note that for the SeMet SAD data sets Bijvoet pairs were not
merged.
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Full details are given in Supplementary Data. AhQnr
deletion mutants were generated in a variant of the recom-
binant protein, bearing a C-terminal hexahistidine tag and
expressed in the pET-26b vector, using the Quikchange II
directed mutagenesis kit (Agilent). Mutant proteins were
expressed as above (AhQnr-6His and loop2) or in E. coli
ArcticExpress (DE3) (Agilent; loop1 and double) and
puriﬁed by nickel-afﬁnity and size exclusion
chromatography.
Modelling of the AhQnr:DNA gyrase complex
A partial model of E. coli DNA gyrase was constructed by
combining the crystal structure of the E. coli GyrA 59kDa
fragment [PDB accession 1AB4; (44)] and an homology
model of the E. coli TOPRIM domain. The latter was
generated by ﬁtting the E. coli TOPRIM sequence
(GyrB residues 406–453, 622–638 and 728–799; i.e.
removing the insertion region) onto the equivalent
portion of Streptococcus pneumoniae DNA topisomerase
IV [(5); PDB accession 3K9F chain C] using Swiss-
PdbViewer (45) and SwissModel [(46); http://swissmodel
.expasy.org/]. The relative orientation of the E. coli GyrA
and TOPRIM fragments in the complex was obtained by
superposition onto their counterparts in S. pneumoniae
topoisomerase IV using PyMOL. AhQnr (monoclinic
crystal form) was then manually docked into the
G-segment binding groove of the resulting structure. Of
the available type IIA DNA topoisomerase crystal struc-
tures, that of S. pneumoniae topoisomerase IV (5) was
chosen as the most appropriate template as this both
includes DNA (ensuring that the individual protein
domains are appropriately oriented to accommodate the
AhQnr structure) and is assembled from individual
subunits rather than a single fused polypeptide.
The modelled complex was then edited by removal of the
methyl groups from methylated lysines in the AhQnr struc-
ture, automatic addition of missing heavy atoms and
manual rotation, along the Ca-Cb bonds, of the side
chains of clashing residues, using Swiss-PdbViewer. The
resulting structure was then prepared for minimization
using the tLEaP module of the AMBER 10 software
package (47) by neutralizing with Na
+ ions and solvating
in a truncated octahedron of TIP3P water molecules (48)
with a minimal thickness of 5A ˚ around the proteins. The
resulting system of 137856 atoms was minimized using the
SANDER module of AMBER 10 and the 03 force ﬁeld
described by Duan et al. (49) for 1000 steps (500 steepest
decent and 500 conjugate gradient). The AMBER calcula-
tions were carried out at the Center for Macromolecular
Modelling and Materials Design at California State
Polytechnic University, Pomona, CA, USA.
RESULTS AND DISCUSSION
AhQnr, the Qnr family member from Aeromonas
hydrophila ATCC 7966
Our initial investigations of Qnr proteins of clinical origin,
were hampered by the poor solubility and tendency to
aggregate of the recombinant protein (QnrB2) or
difﬁculties with expression (QnrS1). Accordingly, we
sought to identify a soluble Qnr homologue from a
Gram-negative organism that was more amenable to struc-
tural and biophysical characterization. Bioinformatics
methods [Supplementary Figure S3; (50)] identiﬁed an orf
from Aeromonas hydrophila ATCC 7966 (AhQnr) as a
Gram-negative Qnr family member of likely high solubil-
ity, while sequence alignment and phylogenetic analysis
(Supplementary Figures S1 and S2) conﬁrmed this
protein to be a member of the Qnr superfamily that is
distinct from orfs found in Gram-positive organisms.
AhQnr cloned in the pET-26b T7 expression vector
was readily over-expressed in E. coli BL21 and related
strains and puriﬁed to homogeneity by ion-exchange,
heparin afﬁnity and size exclusion chromatography.
Far-UV CD spectroscopy (Figure 1A) showed the
puriﬁed protein to adopt the predicted b-conformation
and yields a spectrum resembling that previously
reported for the pentapeptide repeat protein Rfr32 (30).
The results of analytical ultracentrifugation (AUC) experi-
ments (Figure 1B), performed at a range of spin speeds
and protein concentrations, were well described by a
dimer-only model (MW 46 200 Da) as evidenced by the
random deviation of the residual plot (Figure 1B; inset),
and in excellent agreement with the molecular weight
of 48 473 Da calculated from the amino acid sequence.
We found no evidence of dissociation to monomers across
the entire concentration range of our experiments
(minimum concentration of 4.5mM as estimated from
the y-axis intercept on Figure 1B). Importantly, basal
levels of AhQnr expression (i.e. in the absence of
inducer) conferred an increase in minimal inhibitory
concentration (MIC) for various quinolone antibiotics
of 2- to 4-fold on host E. coli strains, consistent with
levels of protection previously reported when other Qnr
family members from environmental bacteria are over-
expressed in E. coli [Supplementary Table S2; (23,51,52)]
and indicative of an ability to protect E. coli type IIA
DNA topoisomerases from quinolone action. In vitro
assays of the supercoiling activity of E. coli DNA gyrase
conﬁrmed this. In line with previous reports of the
activity of other Qnr proteins (34,36–38), but distinct
from the activity of the Gram-positive Qnr homologue
MfpA (36), micromolar concentrations of AhQnr relieve
supercoiling inhibition by the ﬂuoroquinolone
ciproﬂoxacin (Figure 1C).
Structure of AhQnr
In an effort to establish a structural basis for the distinctive
activities of AhQnr, and of other Qnr family members
from Gram-negative bacteria, we determined structures
of AhQnr in two crystal forms to a maximal resolution
of 2.0A ˚ . MolProbity (53) analysis of the ﬁnal reﬁned struc-
tures reveals both to be of excellent stereochemical quality.
To our knowledge, these are the ﬁrst crystal structures for
any Qnr family member from a Gram-negative bacterium.
AhQnr (Figure 2) folds into the right-handed b-helix struc-
ture characteristic of PRPs (54), in which each face of the
quadrilateral b-helix is formed by 5 amino acids, and 20
3920 Nucleic Acids Research, 2011,Vol.39, No. 9amino acids make up one complete coil (Supplementary
Figure S4). Nine complete coils are present in the AhQnr
structure (Figure 2A). The AhQnr dimer is formed by
interactions between the C-termini of each monomer
involving a b-strand (residues 195–199)–a-helix–b-strand
(residues 211–215) dimerization motif. PISA (55) analysis
of the dimer interface reveals a buried surface area of
1019.2 A ˚ 2 per monomer and a total of 13 hydrogen
bonds involved in interdomain interactions. Notably,
strand-exchange between the ﬁnal strand of the b-helix
structure (residues 195–199) and the C-terminal b-strand
(residues 211–215) of the opposing subunit makes a prom-
inent contribution to the dimer interface. Although the
AhQnr dimer forms an essentially straight rod-like struc-
ture, the helical axis of each individual monomer bends
towards its C-terminal end. Two structural features con-
tribute to this distortion. First, between residues 167 and
171 the sequence of b-strands is interrupted by a short
a-helix, opening up the b-helix structure between coils 7
and 8, and 8 and 9. Second, at this point the side chain of
Trp-168 penetrates the interior of the b-helix, further
displacing coil 9 away from coil 8.
Signiﬁcantly, the AhQnr b-helix structure is also inter-
rupted by two loop insertions: a smaller loop (loop1;
residues 49–55) in the middle of coil 3, and a larger one
(loop2; residues 105–115) between coils 5 and 6. While the
conformation of loop1 is essentially ﬁxed, that of loop2
differs in the two (independently reﬁned) subunits of the
AhQnr dimer and between the structures determined in
the two crystal forms (Supplementary Figure S4). In
both the monoclinic and orthorhombic structures, loop2
is also involved in crystallographic contacts between
adjacent dimers in the crystal. Taken together, these
results indicate that loop2 is likely to be conformationally
ﬂexible in solution.
To look for additional functional insights, we analysed
the pattern of amino acid conservation and the distribu-
tion of surface charge in the AhQnr crystal structure.
Mapping conserved amino acids [identiﬁed from an align-
ment of 61 Qnr family members from Gram negative
bacteria (Supplementary Figure S1)] onto the surface of
the AhQnr structure (Figure 2B) shows that, while
sequence conservation is more evenly distributed than
charge across all faces of the protein, face 1 contains a
cluster of conserved amino acids in the central portion
of the b-helix structure. Furthermore, loop2 is largely
composed of conserved residues, including positions
(Ile-107, Phe-113 and Cys-114) that are invariant across
all 61 proteins in the alignment, whereas the composition
of loop1 is more variable. Electrostatic surface calcula-
tions indicate that AhQnr is a strongly negatively
charged protein, but that this charge is not uniformly
distributed. Speciﬁcally, negative charge is localized in a
distinctive ‘stripe’ across one surface of the protein
(formed by faces 1 and 2; Figure 2C) whereas the
opposite side is comparatively less strongly charged.
Comparison of Qnr family structures
Comparison of the AhQnr structure with those of Qnr
family members from Gram-positive bacteria: M. tubercu-
losis MfpA [PDB accession 2BM4; (27)] and E. faecalis
EfsQnr [PDB accession 2W7Z; (28,29)], reveals several
features that distinguish AhQnr from these relatives
(Figure 3). AhQnr contains nine complete PRP coils
compared to MfpA (eight) or EfsQnr (eight complete
coils and an incomplete ninth). The structures differ at
their N-termini: the ﬁrst (N-terminal) coil of the AhQnr
structure is interrupted by a short a-helix (residues 13–18),
Figure 1. AhQnr is a b-structured dimeric protein that protects DNA
gyrase from inhibition by ﬂuoroquinlones. (A) Far-UV CD spectrum of
puriﬁed recombinant AhQnr (21.1mM). (B) Analytical ultracentrifuga-
tion (14000rpm) of AhQnr (5.3mM). Open circles are raw data, solid
line shows best ﬁt to a dimer-only model of MW 46200kDa. Inset
shows deviation of experimental data from ﬁt (residuals). (C) AhQnr
rescues DNA gyrase (2U) from inhibition by the ﬂuoroquinolone
ciproﬂoxacin (6mM). Assay of ATP-dependent supercoiling activity of
E. coli DNA gyrase. Lanes: N, negative control (relaxed pBR322 only;
500ng); P, positive control (relaxed pBR322 plus DNA gyrase); 0,
relaxed DNA plus DNA gyrase plus ciproﬂoxacin (6mM); 0.175–1.4;
as zero plus AhQnr at given concentrations (mM). Positions of migra-
tion for relaxed forms and supercoiled pBR322 DNA are labeled as R
and S, respectively.
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ture. The EfsQnr N-terminus packs onto the exterior of
the structure before crossing the centre of the quadrilateral
b-helix and forming an incomplete ﬁrst coil. The degree
and nature of distortion along the b-helix axis also differs
between the three structures. The AhQnr b-helix bends
between coils 7 and 9 (see above); whereas in MfpA
Pro-81 introduces a distortion between coils 4 and 5.
The ﬁrst seven coils of EfsQnr form a straight rod that
is disrupted by insertion of the side chain of Trp-149 into
the b-helix interior, bending the helical axis at this point
and moving coil 8 away from coil 7. Trp-149 does not
however occupy an equivalent position to AhQnr
Trp-168 (see above). The structures also differ in the
relative orientations of the two monomers in the overall
dimeric structure. While the AhQnr dimer forms a straight
rod, both the MfpA and EfsQnr structures bend about
the dimer interface, inducing a degree of curvature to
the overall structure that is most pronounced for
EfsQnr. Comparison of the electrostatic surface potentials
of the three proteins (Figure 3D) shows that, while all are
negatively charged, AhQnr both carries the strongest
charge and has the most localized charge distribution.
Mutation of AhQnr loops
The most striking difference between the AhQnr structure
and those of MfpA and EfsQr remains the presence of the
two insertion sequences, loops 1 and 2 (above), in the
AhQnr PRP b-helix structure. While similar loops are
present in some other PRPs (31–32), this feature has not
been previously observed in structures of Qnr family
members determined to date [i.e. MfpA (27) and EfsQnr
(28,29)]. Further, the high degree of sequence conservation
in the region of loop2 leads us to hypothesize that this
loop in particular is likely to represent a common
feature of Qnr family members from Gram-negative
bacteria. To investigate whether AhQnr loops 1 and 2
Figure 2. Crystal structure of AhQnr. (A) Ribbon diagram of AhQnr dimer (monoclinic crystal form). Individual monomers are colour-ramped from
N- (blue) to C- (red) termini. Individual coils are numbered 1–9 from N- to C-terminus (right hand panel; A chain). (B) Rendered surface of AhQnr
structure showing pattern of sequence conservation across Qnr family members from Gram-negative bacteria derived from the sequence alignment
shown in Supplementary Figure S1. Faces are labelled as deﬁned from the pentapeptide repeat sequence as shown in Supplementary Figure S4.
Residues coloured red are completely conserved, those coloured blue show over 80% similarity. (C) Rendered surface of AhQnr structure showing
electrostatic surface potential as calculated using APBS (60). This ﬁgure, and Figure 3 were generated using PyMOL (www.pymol.org).
3922 Nucleic Acids Research, 2011,Vol.39, No. 9are of functional importance, we therefore constructed
deletion mutants in which either (loop1, deletion of
residues 49–54; loop2, deletion of residues 105–114) or
both (double) loops were removed, and tested their
ability to protect the supercoiling activity of DNA
gyrase from ciproﬂoxacin inhibition. In order to facilitate
puriﬁcation of poorly expressed mutant proteins these
were constructed in a variant of recombinant AhQnr
(AhQnr-6His) bearing a C-terminal hexahistidine tag.
DNA gyrase supercoiling protection assays conﬁrmed
that, in line with previous reports for other recombinant
Qnr proteins (35–37), incorporation of this tag had no
effect upon AhQnr activity (compare Figures 1C and
4A). Importantly, CD spectroscopy indicates that all
three mutants retained wild-type like secondary structure
(Supplementary Figure S5A) and size exclusion chroma-
tography conﬁrms that all form dimers in solution
(Supplementary Figures S5B and S5C).
The results of supercoiling protection assays are shown
in Figure 4. For the wild-type His-tagged protein
(AhQnr-6His), inhibition of DNA gyrase supercoiling
activity by ciproﬂoxacin (6mM) is signiﬁcantly relieved at
submicromolar AhQnr concentrations (Figure 4A). In the
case of the loop1 mutant, micro-, rather than
submicro-molar, AhQnr concentrations are required to
achieve equivalent levels of protection, but protection
activity is nonetheless clearly evident (Figure 4B). In
contrast, for both the loop2 (Figure 4C) and double
(Figure 4D) mutants, no protective activity is observed in
this AhQnr concentration range (up to 5mM AhQnr).
These data demonstrate that, while both loops 1 and 2
participate in protection of DNA gyrase activity from in-
hibition by quinolones, loop2 makes the major contribu-
tion to this process. None of the mutants showed
detectable inhibition of supercoiling activity in the
absence of ciproﬂoxacin (Supplementary Figure S6) at
AhQnr concentrations of up to 40mM. Although few
studies to date have investigated the effects of introduced
mutations on the activity of Qnr proteins (and none to our
knowledge on protection of DNA gyrase from quinolones
in an in vitro supercoiling assay), these results are in accord
with a previous investigation of QnrA1, QnrB1 and QnrS1,
where quinolone MICs were reduced by mutations in the
highly conserved FCSA motif within loop2 (AhQnr num-
bering from Phe-113) (56). Taken together, these results
suggest that the conserved loop2 may play a common
role in the protection of DNA topoisomerases from quin-
olone action by Qnr proteins of Gram-negative bacteria.
A model for the interaction of AhQnr with DNA gyrase
To further investigate the possible roles of loops 1 and 2 in
the interaction of AhQnr with DNA gyrase, we con-
structed a model of the AhQnr:DNA gyrase interaction
Figure 3. Structures of Qnr family members. (A) AhQnr (chain A, blue; chain B, green); (B) M. tuberculosis MfpA [(27); PDB accession 2BM4;
chain A, cyan; chain B, magenta]; (C) E. faecalis EfsQnr [(28); PDB accession 2W7Z; chain A, orange; chain B, red]. Residues introducing bends into
the PRP structure (AhQnr Trp-168; MfpA Pro-81; EfsQnr Trp-149) are shown as sticks. (D) Electrostatic surface potentials (as calculated using
APBS) mapped onto rendered surfaces for AhQnr (left), MfpA (centre) and EfsQnr (right).
Nucleic Acids Research,2011, Vol.39, No. 9 3923using the monoclinic AhQnr structure and the E. coli
gyrase A 59kDa and gyrase B TOPRIM domain frag-
ments (respectively, 82 and 84% identical in sequence to
their counterparts in the A. hydrophila enzyme) as
described. The results are shown in Figure 5. Similar to
previously published observations with MfpA (27),
AhQnr may be readily placed into the gyrase structure
such that the negative charge on faces 1 and 2 provides
electrostatic complementarity with the positively charged
‘saddle’ of GyrA. However, this orientation also enables
both loops 1 and 2 to make additional contacts with the
GyrAB complex on opposite sides of the central DNA-
binding cleft. First, loop1 is positioned to contact the
GyrB TOPRIM domain on the exterior face of the
molecule (i.e. outside and perpendicular to the DNA-
binding groove) via the a-helices (residues 771–781 and
785–794, E. coli numbering) at its C-terminus. Second,
loop2 contacts the surface of the GyrA ‘tower’ domain,
formed by the a-helices 272–284 and 313–323 (E. coli
numbering), that extends above the central groove.
Notably, the spacing of the two loops along the long
axis of the AhQnr dimer is such that loops 1 and 2 of
each monomer are positioned to make equivalent
contacts with the GyrAB complex, with the spacing of
loop1 matching that of the exterior surfaces of the two
GyrB TOPRIM domains. This orientation also positions
the majority of conserved residues on the AhQnr surface
(Figure 2B above) in direct contact with gyrase (Figure 5,
right-hand panel). Signiﬁcantly, the surfaces of the GyrA
tower and GyrB TOPRIM domains, that our model
suggests may be involved in interactions with AhQnr,
are also highly conserved across DNA gyrases from
Gram-negative bacteria. Together, these observations
indicate that the mode of binding that we postulate here
may be generally applicable to interactions between DNA
gyrase enzymes and Qnr proteins in Gram-negative
bacteria.
Concluding remarks
The data reported here represent the ﬁrst structural char-
acterization for a Qnr protein from a Gram-negative bac-
terium, and the most comprehensive characterization to
date of a Qnr protein from an environmental organism,
as opposed to a clinical isolate. We show that, consistent
with previous results from other aquatic organisms such as
Vibrio, Shewanella and Stenotrophomonas spp. (22–26),
A. hydrophila contains a chromosomal pentapeptide
repeat protein (AhQnr) that in its recombinant form
both increases the quinolone MIC of host E. coli and
protects E. coli DNA gyrase from quinolone inhibition
in in vitro assays of supercoiling activity. These data
show AhQnr to be a novel member of the Qnr protein
family and indicate that, as has previously been the case
for organisms such as Shewanella spp. (22), Aeromonas
spp. represent an additional potential source of new Qnr
resistance determinants that may in the future be exploited
by more clinically important organisms. Thus our study
provides further evidence that environmental, particularly
aquatic, bacteria contain functional resistance genes with
the potential to impact on the effectiveness of clinically
important antibiotics (57,58).
Figure 4. Deletion of surface loops abrogates DNA gyrase protection from ciproﬂoxacin by AhQnr. ATP-dependent supercoiling activity of DNA
gyrase (2 U) in the presence of ciproﬂoxacin (6mM), AhQnr and mutants. (A) AhQnr-6His, (B) loop1, (C) loop2, (D): double. Lane Q: pBR322
DNA plus AhQnr only (4mM). Other lanes are labelled as above (Figure 1C).
3924 Nucleic Acids Research, 2011,Vol.39, No. 9The AhQnr crystal structure reveals a number of
features that appear common to the various Qnr
proteins of Gram-negative origin. While AhQnr has the
expected pentapeptide repeat fold and forms dimers in
solution and in the crystalline state, it is distinguished
from known structures of other Qnr family members by
virtue of the two extended loops, loop1 and loop2, that
project from the pentapeptide repeat b-helix structure.
Our mutagenesis experiments show that, while both
loops make signiﬁcant contributions to the quinolone-
protection activity of AhQnr, the larger of the two,
loop2, is essential to this function. Multiple sequence
alignments indicate that both loops are likely to be
present, and that the sequence of loop2 is well conserved,
in Qnr family members from other Gram-negative
bacteria. Docking experiments suggest that both loops
are well positioned to interact with both the GyrA and
GyrB subunits of DNA gyrase. We propose this to be a
structural and functional motif, important to the DNA
gyrase:Qnr interaction, that is common to Qnr proteins
from Gram-negative bacteria of both environmental and
clinical origin.
Oneofthemostintriguing aspectsofQnrbiochemistry is
the difference between the reported activities of
characterized family members from Gram-positive
(M. tuberculosis MfpA) and Gram-negative (E. cloacae
QnrB4) organisms. Speciﬁcally, MfpA is a sub-micromolar
DNA gyrase inhibitor that does not affect the interaction
with quinolones, whereas QnrB4 is a weak DNA gyrase
inhibitor that protects the enzyme from quinolone inhib-
ition (36). Our data show that in this respect AhQnr is
similar to QnrB4, suggesting that the combination of
weak DNA gyrase inhibition with quinolone protection
activity may be common to Qnr proteins of Gram-
negative origin. While we cannot provide a deﬁnitive ex-
planation for the differing properties of the various Qnr
family members, our model of the AhQnr:DNA gyrase
interaction has features pertinent to this issue. In compari-
son with MfpA, AhQnr (and by implication other Qnr
proteins from Gram-negative bacteria) possesses
additional structural features, loops1 and 2, that make
more extensive interactions with DNA gyrase that in part
involve regions outside the central DNA-binding groove.
In the case of loop1, these interactions involve the GyrB
(TOPRIM domain), rather than the GyrA, subunit of
DNA gyrase. Available crystal structures for the DNA
gyrase DNA binding and cleavage core (59) indicate that
the GyrB TOPRIM domain can adopt multiple orienta-
tions in the context of the GyrAB heterotetramer. Thus,
binding of Qnr proteins may be sensitive to DNA gyrase
conformation; i.e. a speciﬁc orientation of the GyrA and
GyrB subunits relative to one another may be required for
high-afﬁnity Qnr binding. The implication is that the
appropriate conformation may be stabilized in
quinolone-containing complexes, enabling Qnr proteins
to disrupt the quinolone:DNA gyrase interaction, but is
less favoured in their absence, resulting in only weak inhib-
ition of DNA gyrase activity by Qnr proteins when quin-
olones are absent. We propose that the interactions,
involving loops 1 and 2, that we have here identiﬁed repre-
sent a possible mechanism by which this discrimination
between DNA gyrase conformations may be achieved.
Note added in proof
While this manuscript was in revision, a crystal structure
of K. pneumoniae QnrB1 was deposited in the PDB
(accession 2XTW). The structure conﬁrms the presence
of loops 1 and 2 in a Qnr protein of clinical origin.
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Figure 5. Model for interaction of AhQnr with DNA Gyrase. Figure shows minimized model of the complex of AhQnr with DNA gyrase A (59kDa
fragment) plus gyrase B TOPRIM domain. GyrA is coloured blue except for winged helix (residues 56–136, cyan) and tower (residues 236–327,
green) domains. GyrB TOPRIM domain is coloured magenta. AhQnr is coloured according to sequence conservation of Qnr family members from
Gram-negative bacteria as described (Supplementary Figure S1). Left hand and centre panels: views of complex in two orientations at 90  separation.
Right-hand panel: view as centre with one GyrA and one GyrB fragments removed showing involvement of conserved AhQnr residues in proposed
interaction.
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